Given the intriguing roles of PAF-R agonists in modulating the growth of experimental melanoma and NMSC in response to diverse stimuli [7,15,19,23,24,25,26], the current study was designed to determine if systemic PAF-R agonist exposure modulates DMBA/PMA-induced cutaneous carcinogenesis. This evidence concerns the gene PTAFR and melanoma.